A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma
ConditionUterine Cervical Neoplasms
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorLili
About this trial
Cervical large cell neuroendocrine carcinoma (LCNEC) exhibits highly aggressive biological behavior, including strong invasiveness, a high propensity for metastasis, drug resistance, and poor prognosis, necessitating heightened clinical and pathological awareness. This study aims to summarize the clinical characteristics of LCNEC and analyze various prognostic factors to enhance understanding and vigilance toward this disease. Combined with precise pathological diagnosis, improving diagnostic accuracy is crucial for formulating treatment strategies and assessing patient prognosis.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma.
Treatment groups
200 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Lili
Lead sponsor
Tongji Hospital
Sponsor institution
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
Cancer Research Institute of Zhongshan City
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
Qilu Hospital of Shandong University
Collaborator
Fujian Province Tumor Hospital
Collaborator
Fujian Maternity and Child Health Hospital
Collaborator
Zhejiang Cancer Hospital
Collaborator
The Third Affiliated Hospital of Kunming Medical College.
Collaborator
Obstetrics & Gynecology Hospital of Fudan University
Collaborator
Women's Hospital School Of Medicine Zhejiang University
Collaborator
National Cancer Center, China
Collaborator
Peking Union Medical College Hospital
Collaborator
The Affiliated Tumor Hospital of Xinjiang Medical University
Collaborator
The First Affiliated Hospital of Anhui Medical University
Collaborator
Tianjin Medical University Cancer Institute and Hospital
Collaborator
Renmin Hospital of Wuhan University
Collaborator
Source ClinicalTrials.gov